Pulmonx Corp

The company is a commercial-stage medical technology business that develops and provides minimally invasive treatments for patients suffering from severe emphysema, a form of chronic obstructive pulmonary disease. Its core solution combines the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System, and the LungTraX cloud-based analysis platform. In addition, the business manufactures the AeriSeal System, an investigational synthetic polymer foam designed to close collateral air channels in targeted lung lobes. The enterprise primarily sells its products directly to hospital customers, while focusing its sales and educational initiatives on interventional pulmonologists performing pulmonary procedures.

The business commercializes its products internationally across North America, Europe, and the Asia Pacific region, maintaining market access in countries such as the United States, Australia, Austria, Belgium, France, Germany, Japan, the Netherlands, South Korea, Switzerland, and the United Kingdom. It relies on a direct sales force in principal markets alongside distributor networks in smaller or emerging territories. The provided text does not state the location of the company's headquarters.

Summary of the business section of Pulmonx's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had a total of 296 full time employees, with 229 employees in the U.S., 56 in Europe, and 11 in Asia Pacific.”